Bioventus BVS Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $3.95M+219% | $17.32M+2,972% | $4.01M+169% | $9.27M+127% | -$3.32M+47.9% | ||
| $11.21M-5.6% | $11.69M-5.7% | $11.4M-7.1% | $12.05M-8.0% | $11.87M+0.7% | ||
| $3.26M+35.2% | $3.44M+70.6% | $3.18M+27.5% | $3.64M-36.9% | $2.41M-19.3% | ||
| $135K+214% | -$1.13M— | $135K+126% | $44K+101% | $43K-46.9% | ||
| $0+100% | $0+100% | $1K— | -$1K— | -$81K— | ||
| $230K-64.6% | $312K— | $101K+233% | $193K— | $650K+167% | ||
| -$7.32M+18.7% | —— | —— | $13.63M-31.8% | -$9M-560% | ||
| $2.65M+40.8% | -$12.97M-333% | -$291K-112% | $2.81M-34.5% | $1.88M-53.8% | ||
| -$15.37M+60.7% | -$4.44M-127% | —— | —— | -$39.1M-433% | ||
| $275K-27.8% | $155K-87.6% | $243K-59.4% | $382K+0.5% | $381K-34.4% | ||
| $8.93M+146% | $37.97M+96.5% | $30.1M+192% | $25.94M+71.1% | -$19.33M-222% | ||
| $574K-30.5% | $580K+1.0% | $473K+639% | $683K+787% | $826K+184% | ||
| -$574K+30.5% | -$580K-102% | -$473K-639% | -$1.37M-1,678% | -$826K+17.4% | ||
| $0-100% | $25M+66.7% | $10M— | $5M— | $5M— | ||
| $120K-20.0% | $511K-53.7% | $96K-82.6% | $1.32M+116% | $150K-15.3% | ||
| $1.04M— | —— | —— | —— | $0— | ||
| $0-100% | —— | —— | $10.77M— | $9M— | ||
| —— | $174.25K-40.9% | $174.25K-40.9% | $174.25K-40.9% | $174.25K-40.9% | ||
| -$23.14M-2,544% | -$28.45M+33.6% | -$19.98M— | -$14.66M-86.9% | $947K+122% | ||
| -$608K-241% | $133K+106% | —— | $202K+148% | $430K+179% | ||
| -$15.39M+18.0% | $9.07M— | $9.25M-16.5% | $10.11M— | -$18.78M-59.3% | ||
| -$54K-122% | $27K-78.6% | $0-100% | $123K+177% | $242K+164% | ||
| $0+100% | $0+100% | $1K— | -$1K— | -$81K— | ||
| $230K-64.6% | $312K— | $101K+233% | $193K— | $650K+167% | ||
| —— | -$171.5K-103% | -$171.5K-103% | -$171.5K-103% | -$171.5K-103% | ||
| —— | $16.44M— | $16.44M— | $16.44M— | $16.44M— | ||
| —— | $0-100% | $0-100% | $0-100% | $0-100% | ||
| -$220K-8.4% | -$208K-7.2% | -$207K-8.4% | -$209K-10.0% | -$203K-10.9% | ||
| $0-100% | $25M+66.7% | $10M— | $5M— | $5M— | ||
| $534K+281% | $22K— | $22K— | $56K— | $140K-35.8% | ||
| $0-100% | —— | —— | $10.77M— | $9M— | ||
| $0-100% | —— | $30M— | —— | $15M— | ||
| $8.36M+141% | $37.39M+99.4% | $29.63M+189% | $25.26M+67.4% | -$20.16M-220% | ||
| $8.36M+141% | $37.39M+99.4% | $29.63M+189% | $25.26M+67.4% | -$20.16M-220% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Bioventus generate?
- Bioventus (BVS) generated $102.9M in operating cash flow over the trailing twelve months.
- What is Bioventus's free cash flow?
- After $2.3M of capital expenditures, Bioventus's free cash flow was $100.6M over the trailing twelve months, up 320.5% year over year.
- Where does Bioventus's cash flow data come from?
- Every line is extracted from Bioventus's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
